Gen, Soei
Tanaka, Ichidai
Morise, Masahiro
Koyama, Junji
Kodama, Yuta
Matsui, Akira
Miyazawa, Ayako
Hase, Tetsunari
Hibino, Yoshitaka
Yokoyama, Toshihiko
Kimura, Tomoki
Yoshida, Norio
Sato, Mitsuo
Hashimoto, Naozumi
Article History
Received: 9 March 2022
Accepted: 6 June 2022
First Online: 14 June 2022
Declarations
:
: This study was conducted with the approval of the ethical review committee of Nagoya University Hospital (approval number:2018–017) and in accordance with the guidelines of the Declaration of Helsinki. The study is retrospective cohort study and only anonymized clinical information of patients was collected without interfering with patients’ treatment plans or posing physiological risks to patients. Informed consent was waived by the same ethical review committee of Nagoya University Hospital. Information about this research, including the purpose, is available on the website of Nagoya University School of Medicine and patients are given the opportunity to refuse to participate in this study.
: Not applicable.
: T.H. received research funding from Boehringer Ingelheim. N.H. reported receiving grant from Boehringer Ingelheim; Pfizer Inc.; Astellas Pharma Inc.; Ono Pharmaceutical Co.; Shionogi & Co.; AstraZeneca; Sanofi K.K.; Teijin Limited; MSD K.K.; Meiji Seika Pharma Co.; Daiichi Sankyo Company, Limited; GlaxoSmithKline K.K.; Otsuka Pharmaceutical Co.; KYORIN Pharmaceutical Co., Ltd.; Sumitomo Dainippon Pharma Co.; Novartis Pharma K.K.; Kyowa Hakko Kirin Co.; Eli Lilly Japan K.K.; and Chugai Pharmaceutical Co. that was paid to Nagoya University. Other authors report no conflict of interest in this work.